In 2020, private equity firm Arsenal Capital Partners acquired BresMed and Cello, two independent biopharma companies. Now, BresMed and Cello will combine to offer unique solutions to their clients. These companies have experience in health economic and outcomes research and in advising global healthcare companies.
According to Group CEO Jon Williams, “By bringing these two organizations together we are enabling a diverse set of industry experts to collaborate to tackle some of the biopharma industries toughest problems,” adding, “We are very excited about the innovative new methods and cutting-edge scientific capabilities that both BresMed and Cello will continue to deliver.” Learn more here.
(Source: BresMed, 2/9/21)